A pharmacogenetic study of vorinostat glucuronidationKANG, Soonmo Peter; RAMIREZ, Jacqueline; HOUSE, Larry et al.Pharmacogenetics and genomics (Print). 2010, Vol 20, Num 10, pp 638-641, issn 1744-6872, 4 p.Article

Vorinostat-induced bone loss might be related to drug toxicitySONG XU; DE VEIRMAN, Kim; VANDERKERKEN, Karin et al.Bone (New York, NY). 2013, Vol 57, Num 2, pp 384-385, issn 8756-3282, 2 p.Article

Dimethyl sulfoxide to vorinostat : development of this histone deacetylase inhibitor as an anticancer drugMARKS, Paul A; BRESLOW, Ronald.Nature biotechnology (Print). 2007, Vol 25, Num 1, pp 84-90, issn 1087-0156, 7 p.Article

Inhibition of cell-mediated immunity by the histone deacetylase inhibitor vorinostat: Implications for therapy of cutaneous T-cell lymphomaSTEPHEN, Sasha; MORRISSEY, Kelly A; BENOIT, Bernice M et al.American journal of hematology. 2012, Vol 87, Num 2, pp 226-228, issn 0361-8609, 3 p.Article

Deciphering the Molecular Events Necessary for Synergistic Tumor Cell Apoptosis Mediated by the Histone Deacetylase Inhibitor Vorinostat and the BH3 Mimetic ABT-737WIEGMANS, Adrian P; ALSOP, Amber E; JOHNSTONE, Ricky W et al.Cancer research (Chicago, Ill.). 2011, Vol 71, Num 10, pp 3603-3615, issn 0008-5472, 13 p.Article

Suberoylanilide hydroxamic acid (SAHA; vorinostat) causes bone loss by inhibiting immature osteoblastsMCGEE-LAWRENCE, Meghan E; MCCLEARY-WHEELER, Angela L; SECRETO, Frank J et al.Bone (New York, NY). 2011, Vol 48, Num 5, pp 1117-1126, issn 8756-3282, 10 p.Article

HDAC inhibitors : Clinical update and mechanism-based potentialGLASER, Keith B.Biochemical pharmacology. 2007, Vol 74, Num 5, pp 659-671, issn 0006-2952, 13 p.Article

Impact of UDP-gluconoryltransferase 2B17 genotype on vorinostat metabolism and clinical outcomes in Asian women with breast cancerWONG, Nan-Soon; SEAH, Elaine Z. H; GOH, Boon-Cher et al.Pharmacogenetics and genomics (Print). 2011, Vol 21, Num 11, pp 760-768, issn 1744-6872, 9 p.Article

Solubilization of vorinostat by cyclodextrinsCAI, Y. Y; YAP, C. W; WANG, Z et al.Journal of clinical pharmacy and therapeutics (Print). 2010, Vol 35, Num 5, pp 521-526, issn 0269-4727, 6 p.Article

Synthesis and biochemical analysis of 2,2,3,3,4,4,5,5,6,6,7,7-dodecafluoroN-hydroxy-octanediamides as inhibitors of human histone deacetylasesHENKES, Leonhard M; HAUS, Patricia; JÄGER, Felix et al.Bioorganic & medicinal chemistry. 2012, Vol 20, Num 2, pp 985-995, issn 0968-0896, 11 p.Article

Proteomic analysis identifies differentially expressed proteins after HDAC vorinostat and EGFR inhibitor gefitinib treatments in Hep-2 cancer cellsBIANCHI, Laura; BRUZZESE, Francesca; BINI, Luca et al.Proteomics (Weinheim. Print). 2011, Vol 11, Num 18, pp 3725-3742, issn 1615-9853, 18 p.Article

Clinical pharmacology profile of vorinostat, a histone deacetylase inhibitorIWAMOTO, Marian; FRIEDMAN, Evan J; SANDHU, Punam et al.Cancer chemotherapy and pharmacology. 2013, Vol 72, Num 3, pp 493-508, issn 0344-5704, 16 p.Article

Vorinostat/SAHA-induced apoptosis in malignant mesothelioma is FLIP/caspase 8-dependent and HR23B-independentHURWITZ, Jane L; STASIK, Izabela; O'BYRNE, Ken J et al.European journal of cancer (1990). 2012, Vol 48, Num 7, pp 1096-1107, issn 0959-8049, 12 p.Article

Contribution of reactivated RUNX3 to inhibition of gastric cancer cell growth following suberoylanilide hydroxamic acid (vorinostat) treatmentCANHUA HUANG; IDA, Hiroshi; ITO, Kosei et al.Biochemical pharmacology. 2007, Vol 73, Num 7, pp 990-1000, issn 0006-2952, 11 p.Article

A phase II study of vorinostat (MK-0683) in patients with polycythaemia vera and essential thrombocythaemiaANDERSEN, Christen L; MCMULLIN, Mary F; LINDER, Olle et al.British journal of haematology. 2013, Vol 162, Num 4, pp 498-508, issn 0007-1048, 11 p.Article

A phase I study of vorinostat in combination with idarubicin in relapsed or refractory leukaemiaKADIA, Tapan M; HUI YANG; NEWSOME, Willie et al.British journal of haematology. 2010, Vol 150, Num 1, pp 72-82, issn 0007-1048, 11 p.Article

The structural requirements of histone deacetylase inhibitors: Suberoylanilide hydroxamic acid analogs modified at the C6 positionSUN EA CHOI; PFLUM, Mary Kay H.Bioorganic & medicinal chemistry letters (Print). 2012, Vol 22, Num 23, pp 7084-7086, issn 0960-894X, 3 p.Article

Vorinostat, a histone deacetylase inhibitor, facilitates fear extinction and enhances expression of the hippocampal NR2B-containing NMDA receptor geneFUJITA, Yosuke; MORINOBU, Shigeru; TAKEI, Shiro et al.Journal of psychiatric research. 2012, Vol 46, Num 5, pp 635-643, issn 0022-3956, 9 p.Article

The structural requirements of histone deacetylase inhibitors: Suberoylanilide hydroxamic acid analogs modified at the C3 position display isoform selectivityEA CHOI, Sun; WEERASINGHE, Sujith V. W; PFLUM, Mary Kay H et al.Bioorganic & medicinal chemistry letters (Print). 2011, Vol 21, Num 20, pp 6139-6142, issn 0960-894X, 4 p.Article

Vorinostat in combination with bortezomib in patients with advanced malignancies directly alters transcription of target genesKOLESAR, Jill M; TRAYNOR, Anne M; BAILEY, Howard H et al.Cancer chemotherapy and pharmacology. 2013, Vol 72, Num 3, pp 661-667, issn 0344-5704, 7 p.Article

Valproic acid stimulates clusterin expression in human astrocytes: Implications for Alzheimer's diseaseNUUTINEN, Tapio; SUURONEN, Tiina; KAUPPINEN, Anu et al.Neuroscience letters. 2010, Vol 475, Num 2, pp 64-68, issn 0304-3940, 5 p.Article

The histone deacetylase inhibitors vorinostat and romidepsin drownmodulate IL-10 expression in cutaneous T-cell lymphoma cellsTIFFON, C. E; ADAMS, J. E; VAN DER FITS, L et al.British journal of pharmacology. 2011, Vol 162, Num 7, pp 1590-1602, issn 0007-1188, 13 p.Article

Vorinostat interferes with the signaling transduction pathway of T-cell receptor and synergizes with phosphoinositide-3 kinase inhibitors in cutaneous T-cell lymphomaWOZNIAK, Magdalena B; VILLUENDAS, Raquel; HERRERA, Marta et al.Haematologica (Roma). 2010, Vol 95, Num 4, pp 613-621, issn 0390-6078, 9 p.Article

Anti-Melanoma Effects of Vorinostat in Combination with Polyphenolic Antioxidant (―)-Epigallocatechin-3-Gallate (EGCG)NIHAL, Minakshi; ROELKE, Craig T; WOOD, Gary S et al.Pharmaceutical research. 2010, Vol 27, Num 6, pp 1103-1114, issn 0724-8741, 12 p.Article

A phase 2 study of vorinostat in acute myeloid leukemiaSCHAEFER, Eric W; LOAIZA-BONILLA, Arturo; JUCKETT, Mark et al.Haematologica (Roma). 2009, Vol 94, Num 10, pp 1375-1382, issn 0390-6078, 8 p.Article